Over a decade ago, a new discipline called network medicine emerged as an approach to understand human diseases from a network theory point-of-view. Disease networks proved to be an intuitive and powerful way to reveal hidden connections among apparently unconnected biomedical entities such as diseases, physiological processes, signaling pathways, and genes.
Introduction
The study of diseases as non-isolated elements and the understanding of how they resemble and relate to each other are crucial to provide novel insights into pathogenesis and etiology, as well as in the identification of new targets and applications for drugs [1] . The complete sequencing of the human genome at the beginning of the 21st century represented a revolution in the study of the relationships between diseases. In combination with the growing availability of transcriptomic, proteomic, and metabolomic data sources, it should help to improve the classification of diseases [2] . However, the use of these sources raised new problems such as their fragmentation, heterogeneity, availability and different conceptualization of their data [3, 4] .
Recent developments in network theory provide a way to address this challenge by representing these complex relationships as a collection of linked nodes [5] . Complex networks theory is a statistical physics interpretation of the old graph theory, aimed at describing and understanding the structures created by the relationships between the elements of a complex system [6] [7] [8] [9] . Those elements are represented by nodes, pairwise connected by links whenever a relationship is observed between the corresponding elements. The resulting structure can then be described by means of a plethora of topological metrics [10] , or be used as a base for modelling the system. The application of this field to biological problems has been named "network biology", while its use in biomedical problems is known as "network medicine" [11] . Some applications of biological networks are protein-protein interaction networks, gene regulatory networks (DNA-protein interaction networks), metabolic networks, signaling networks, neuronal network or phylogenetic trees [12] .
Following this approach, disease networks express the relationship between diseases as nodes and edges in a graph in
, where D represents the set of diseases (nodes) and W the set of their relationships (edges) based upon their similarity. The meaning of similarity varies depending on the data used to build the network, which may be biological (genes or common proteins) or phenotypic (comorbidity, similar symptoms) [13] , among other approaches. As will be explained throughout this article, the concept of disease network is not limited to diseasedisease connections (homogeneous networks), but also to relations between the disease and other factors such as its symptoms, its associated genes or its treatments (heterogeneous networks).
During the past decade, numerous studies have been proposed to improve our understanding of the functioning of diseases and their relationships by creating disease networks based on different disease-disease association models and large-scale data exploitation. Of them, a significant number was oriented to exploit the new discovered relationships between diseases in the reassignment of known compounds for their treatment, the so-called "drug repurposing".
In the first part of this document, we will thoroughly review this previous work, analyzing the evolution of the methodologies used in the creation of disease networks from a timeline perspective up to the state of the art.
Despite their different approaches and methodologies, in the studies dedicated to the improvement of the disease understanding and particularly to drug repositioning, the typical phases of a data science pipeline are observed, such as data extraction, data integration model, 
Review methodology
A comprehensive search of the literature on disease networks and their contribution to disease understanding and drug repurposing was undertaken. Five databases were searched, including PubMed/Medline, Web of Science, Springer, ACM Digital Library, and IEEE Xplore.
The results were restricted to English-language studies published from 2007 (as described in section 3.1, the earliest study reviewed dates from this year) to September 2018.
The following keywords were used for the search: disease network or at least one of "biological network, network medicine"; and at least one of "disease understanding, drug repurposing, drug repositioning, pipeline". The obtained studies were screened by a single researcher and then reviewed by the coauthors, so this work can be considered a "systematized review" [14] .
Analysis of articles followed predetermined eligibility criteria. Studies were included in the review, if the study: (a) addressed the application of biological networks to disease understanding and/or drug repurposing; (b) d the methods to build the network; (c) provided qualitative and quantitative information of the generated network.
Evolution of disease networks and their application to drug repurposing

Early studies
Initial works proposing the use of disease networks for the analysis of their underlying relationships exploited data of biological origin. In 2007, Goh et al. constructed a disease-gene bipartite graph called "Diseasome" using information from OMIM database [1] . From the diseasome they derived the Human Disease Network (HDN), in which pairs of disorders are connected if they have common genes. The study revealed that diseases tend to cluster by disease classes and that their degree of distribution follows a power law; that is, only a few diseases connect to a large number of diseases, whereas most diseases have few links to others.
Aiming to reduce the bias of the HDN towards diseases transmitted in a Mendelian manner [15] , subsequent studies used other sources of biological data. In 2008 year, Lee et al.
constructed a metabolic disease network in which two disorders are connected if the enzymes associated with them catalyze adjacent reactions [16] . In 2009, Barrenas et al. [17] derived a complex disease-gene network (CDN) using GWAs (Genome Wide Association studies). The complex disease network showed that diseases belonging to the same disease class do not always share common disease genes. Complex disease genes are less central than the essential and monogenic disease genes in the human interactome.
The rapid improvement in disease association prediction through the use of network theory fostered its early application to drug repurposing. Drug repurposing is the utilization of known drugs and compounds to treat new indications [18] . Since the repositioned drug has already passed a significant number of toxicity and other tests, its safety is known and the risk of failure for reasons of adverse toxicology are reduced [19] . As a result, the cost and time needed to bring a drug to market is significantly reduced compared to traditional drug development. The commercial applications of drug repositioning and the interest shown by pharmaceutical companies have led to a growing academic activity in this field. This fact is reflected in the evolution of the results for the search by "Drug Repurposing" in Google Scholar, as seen in First studies in drug repurposing using biological networks followed a drug-centric approach based on the "guilt-by-association" assumption, that is, similar drugs may share similar targets and vice-versa [20] . In 2007, Yildrim et al. created a graph composed of US Food and Drug Administration-approved drugs and proteins linked by drug-target binary associations [21] . Similar studies were carried out by Ma'ayan [22] in 2007 and Chiang [23] and Bleakley [24] 
Incorporating textual sources
The abundance of new biological data did not make researches overlook the existence of another important resource: the highest level clinical phenotypes, that is, symptoms. As one of the first and most obvious forms of diagnosis, the relationship between symptoms and diseases is widely documented in clinical records.
One of the earliest studies in network medicine to use these sources was published by Network using a proposed similarity measure for text-mined phenotypes [39] . In both cases, these studies compare their results with gene-based networks, finding that symptom-based similarity of two diseases strongly correlates with the number of shared genetic associations.
They also demonstrated that not only Mendelian diseases tend to be grouped into classes, but also common ones.
Completing the diseasome
Due to the intrinsic complexity of the relationships between diseases, the consideration of a single factor (e.g. gene-disease, symptom-disease or drug-disease) was a limiting factor to obtain novel findings and predicting drug repositioning [18] . In his review of the HDN in 2012,
Goh. et al. proposed that each and every disease-contributing factor such as molecular links from interactome, co-expression and metabolism, as well as genetic interactions and phenotypic comorbidity links, will have to be integrated in a context-dependent manner. Furthermore, drug chemical information and non-biological environmental factors such as toxicity information altogether must also be incorporated [15] . The result will be a combination of general and bipartite network representations into a single, complex, k-partite heterogeneous network referred as the complete Diseasome.In line with this idea, Gottlieb made use of a broader collection of data sources to create five drug-drug similarity measures and two disease-disease similarity measures. These similarity measures were then used by PREDICT, an algorithm to infer novel drug indications [40] . Further studies by Sun [41] Figure 1 , which may lead to wrong inferences. Ultimately, advances towards more comprehensive networks have resulted in tools for the prediction of new treatments given a certain disease, known as Drug Target Indications (DTI). This is the case of Rephetio [47] , a project based on Hetionet [46] that predicted 3394
repurposing candidates by applying an algorithm originally developed for social network analysis [48] . Another example worth mentioning is DTINet [49], a DTI prediction system based on learning low-dimensional feature vectors that showed better performance than other state-ofthe-art prediction methods and discovered the potential application of cyclooxygenase inhibitors in preventing inflammatory diseases.
A data science pipeline to build disease networks
Throughout the previous section, we have seen how the rise of network medicine studies has resulted in a expanding variety of innovative methods for the construction and exploitation of disease networks. However, despite using different strategies, these methods are generally based on determining the similarities and relationships between diseases and their treatments at phenotypic level (comorbidity, side-effects) or biological level (common genes, proteins, compounds). Furthermore, they clearly share common phases such as data ingestion, data processing, analysis, modeling or visualization that can be represented as functional units of a data science pipeline.
The data science pipeline consists in a sequence of stages or functional units that sequentially process some input data in order to solve a certain problem [50] . This concept applies to disease networks, where disease information is processed to discover how diseases relate to each other or how drugs can be repositioned. The pipeline representation also facilitates the reproducibility and the comparison among studies as a whole and also at phase level. Most importantly, it also enhances the reusability and the recombination of the functional units to build new drug-repurposing. Throughout the following subsections, we will describe the process of construction and exploitation of a disease network through the functional units of a data science pipeline.
Data acquisition and processing
The first step in the pipeline is to acquire data from a variety of sources, a process known as data acquisition or data ingestion. As seen in the section 2, the growing availability of information sources has allowed developing different approaches to improve our understanding of diseases and to predict new drug applications.
A significant number of studies use biological data, such as KEGG (genes and pathways) [16] , BioGRID (protein interactions) [4] or OMIM (genes and phenotypes) [1, 28] , among many others. Supplementary Table 1 contains some of the most important sources of biological information, including their type and description. Studies on disease networks focusing on drug repositioning exploit drug databases and their relation to genes, phenotypes and compounds, such as those offered by the FDA [21] [22] [23] [24] or DrugBank [25] [26] [27] [28] 38] , for instance.
Supplementary Table 2 collects the most common drug data sources. Finally, an increasingly significant number of studies use data obtained by mining medical literature sources (e.g.
articles, clinical trials) such as PubMed [38, 39, 51] or the GWAS Catalog [41] . Supplementary   Table 3 contains some of the most relevant sources of medical literature.
A second step in the pipeline consists in transforming and mapping data into a format with the intent of making it more appropriate to work (usually referred as data processing, data wrangling or data munging). Recent studies combine multiple databases to provide more accurate prediction models [4, 45, 46] . However, this poses a challenge when relating identifiers or terms obtained from different sources. To address this problem, researchers use thesauri of terms such as MeSH, SNOMED CT or UMLS; code listings such as ICD or HGNC; and ontologies such as DO, PO, GO or Uberon [39, 52] . Being a valuable source of semantic and hierarchical information themselves, these resources allow mapping data such as disease codes or medical terms. In the case of medical literature sources, the use of metadata (such as MeSH headers in the case of Pubmed, for example) is often combined with terms extraction tools such as MetaMap or cTakes [36] . Supplementary Table 4 lists some of the sources used for data mapping.
The way to exploit the information in these databases varies greatly from one source to another. Largest databases offer online advanced search and provide developers with application programming interfaces (APIs) to facilitate intensive access to data. For example, the NCBI provides the E-utilities, a public API to access all the Entrez databases including PubMed, PMC, Gene, Nuccore and Protein. The Japanese KEGG also provides REST APIs for data consumption. DisGeNET provides an SPARQL endpoint that allows exploration of the DisGeNET-RDF data set and query federation to expand gene-disease association information with data on gene expression, drug activity and biological pathways, among other. In some cases, data can also be downloaded for their consumption through on-premise applications, as in the case of the Disease Ontology or the Gene Ontology, for example. This disparity complicates the use of different sources in research projects. To alleviate this problem, initiatives such as 
Data integration and modeling
In the next steps of the data science pipeline, data previously acquired and processed are integrated and analyzed in order to answer the matter of our study. In other words, a disease network is built by combining the output of the previous stage and a model is constructed from it. Disease networks consist of a set of nodes (mainly, but not only, representing diseases) and a set of edges (connecting diseases directly or through other related node types). Depending on the type of node they connect, network edges can be directed or undirected, weighted or unweighted.
As described in previous sections, over the past decade successive studies based on disease networks have proposed different models of data integration.
Homogeneous networks
1 https://biopython.org Homogeneous disease networks (i.e. those where nodes represent diseases and edges represent direct connections among them) are the simplest type of disease networks. In many studies these networks are built as a projection of a heterogeneous disease network (i.e. a network in which diseases are connected to other types of nodes) [1, 42] . For example, in Figure   3 , the gene-disease bipartite network is projected onto the disease similarity network (DSN) by relating two diseases that have a gene in common. The disease-disease network can then be analysed by using standard network based methods [1, 53] . In a simplistic approach, the link weights in the resulting disease-disease network represent the link multiplicity resulting from the projection. More complex methods, such as hyperbolic weighting or resource allocation weighting, have been proposed as an alternative [54, 55] . In other studies, homogeneous disease networks are built as similarity networks. In these networks, if the similarity score between disease i and j is more than zero, the corresponding vertices are linked by an edge in the network. 
Heterogeneous networks
The projection of heterogeneous networks into homogeneous disease-disease networks allows applying simpler network analysis techniques on the resulting network. However, it often results in information loss. For instance, in Figure 3 by projecting the gene-gene network onto the disease-disease network, the information about gene interactions and their structure is lost. In contrast, heterogeneous networks make it easy to predict relationship between entities of different types, such as diseases, genes or drugs, following a guilt-by-association paradigm [20] .
For example, a drug that regulates a gene associated to a disease could be repurposed for diseases associated to the same gene. Data fusion by matrix factorization and network topology based techniques, such as diffusion and meta-path, are the most common methods for edge prediction in heterogeneous networks, as discussed below Matrix Factorization methods are closely related to clustering (unsupervised) algorithms.
Non-Negative Matrix Factorization (NNMF) decompose matrices of heterogeneous data and data relationships to obtain low-dimensional matrix factors. These factors are then used to reconstruct the data matrices, adding new unobserved data obtained from the latent structure captured by the Metapath-based approaches also preserve the network structure, and additionally provide an intuitive framework and interpretable models and results. A meta-path P is a path defined over the general schema of the heterogeneous network G = (A, R), where A represents the set of nodes and R the set of their relationships. The metapath is denoted by
where l is an index indicating the corresponding metapath [48] . Figure 4 shows the metapaths extracted from an annotated heterogeneous network. 
Model validation
In this analysis of the reconstruction of disease networks, we wanted to give a special relevance to the validation process. Ensuring that the computational pipeline is producing correct and valid results is critical, particularly in a clinical setting [72] . As previously explained, disease networks are used in studies as diverse as the discovery of new disease-disease relationships, the prediction of gene-disease relationships (GDA) or the repositioning of drugs. The validation of the network depends, therefore, on the type of study in question. In general, the validation can be done experimentally or by computational techniques.
Approaches
Experimental conclusions can be misleading. For example, a therapy can offer a short-term benefit, but a longterm harm. Finally, the relevance of animals as models of human disease is questionable, because the networks linking genes to disease are likely to differ between the two species [74, 75] .
In silico is an expression used to mean "performed on computer or via computer simulation." In silico tests have the potential to speed the validation process while reducing the need for expensive lab work. In silico validation requires a point of reference for evaluating the model performance, also known as Criterion Standard or Gold Standard. It is noteworthy that in the field of biomedicine usually the criterion standard is actually the best performing test available under reasonable conditions [76] . For example, in this sense, a MRI is the gold standard for brain tumour diagnosis, though it is not as good as a biopsy [77] . Hence, the most recurrent benchmarks used in the validation in silico of disease networks include consolidated data biomedical sources and medical literature.
While in silico validation is especially appealing because of the ability to rapidly screen candidates and to reduce the number of possible repositioning candidates, it is debatable how useful and reliable such methods are in producing clinically efficacious repositioning hypotheses.
With in silico repurposing approach, there can be a possibility of false positive hits during screening and also the activity of the candidate drug molecules may vary in the in vitro or in vivo systems. Therefore, to validate their potency further in vitro and in vivo studies are needed to be performed [78] .
Sources
Sources of biological, phenotypic or chemical data as well as several available ontologies and code standards (see section 3.1) are used for in silico validation in many studies focusing on disease networks. For instance, their performance to discover disease-disease relationships has been validated with the disease classifications in the Disease Ontology [4, 39] or in the ICD codes [42] , as well as with comorbidity associations downloaded from the Human Disease Network (HuDiNe) [41] . DisGeNET has been used to validate de novo gene-disease associations [79] , as it integrates data from expert curated repositories with information gathered through text-mining of the scientific literature, GWAS catalogues and animal models [80] .
For the validation of drug repositioning predictions, sources such as PharmacotherapyDB and DrugCentral were exploited [47] . However, the heterogeneity in the source of these standards as well as the types of data they contain is detrimental to reproducibility and may lead to claims on extremely high accuracy. Furthermore, the aforementioned sources are inevitably biased towards consolidated knowledge, and therefore they might suffer some limitations in corroborating new discoveries.
As an alternative (or usually, as a complement) to these sources, medical literature (i.e. studies, medical trials, clinical histories) are used for in silico validation of disease network based studies. For instance, Mathur and Paik used previous studies to validate disease-disease and drug-target associations [28, 82] . In some cases, the validation process also combined expert review to corroborate the discoveries [38] .
Methods
Leaving aside the particularities of biomedical research and its sources, the validation of classification or prediction methods based on disease networks does not differ from other validation cases. Therefore, in the analyzed studies we found validation methods widely used.
For example, k-fold cross-validation is often used to check whether the model is an overfit or not [83, 84] . Overfitting is one of the typical problems of validation, especially when limited data sets are available. Information leakage is another common pitfall in model validation, and occurs when biased data (e.g. data on the training labels) leak into the model before cross-validation, making irrelvant features appear as highly predictive and leading to overly optimistic results.
This issue can be prevented by applying nested cross-validation or by excluding certain datasets before the validation process [85, 86] .
To quantify the predictive power of their network-based model, many studies use the Area Under the Curve of the Receiver Operating Characteristic (AUC-ROC), another frequently used method in validation problems [39, 87, 88] . The AUC-ROC is the plot between sensitivity and (1-specificity). The p-value is the probability that the observed sample AUC-ROC could actually correspond to a model of no predictive power (null hypothesis), i.e. to a model whose population AUC-ROC is 0.5. If p-value is small, then it can be concluded that the AUC-ROC is significantly different from 0.5 and that therefore there is evidence that the model actually discriminates between significant and non-significant results [89] . Typically, a threshold value (called significance level) of p-value < 0.05 is used. However, biomedicine studies often use more restrictive values like 0.005 [28] or even 0.001 [4] .
Network exposition, visualization and interaction
Last but not least, at the end of the pipeline the results obtained should come out in a format that can be consumed by the audience (e.g. the scientific community, the media or even ourselves to inform the next iteration). One of the major advantages of disease networks is the intuitive access to the underlying complex interactions between diseases and other diseases, genes or drugs. Thus, publishing not only the data but also means to explore and exploit the network is key to ensure reproducibility and extensibility of the study [90] . Early studies lacked visualize the generated disease networks [39] . In both cases, a force-directed layout was used for the graph drawing [91] .
Advances in network visualization tools have prompted the publication of network exploration systems associated with studies, being Cystoscape 4 a remarkable example. Cytoscape provides basic functionality to layout and query the network; to visually integrate the network with expression profiles, phenotypes, and other molecular states; and to link the network to databases of functional annotations [92] . A number of studies have used Cytoscape as a basis to build and visualize their networks. For instance, Le et al. created HGPEC as an app for
Cytoscape to predict novel disease-gene and disease-disease associations [93] . DisGeNet provided another app that allows to visualize, query and analyse a network representation of DisGeNET database [94] . Many other apps can be found in the Cytoscape app store 5 .
On their side, Himmelstein et al. accompanied their study based on heterogeneous disease networks with a powerful visualization tool built with Neo4j 6 [46] that provides browsing and querying on Hetionet (see Figure 5) . Being a remarkable example of data accessibility, not only the data but also the code of this tool is publicly available. Different studies of the University of Rome, such as SIGNOR 7 and DISNOR 8 , also provides a disease network visualization tool that includes intuitive representations of the interactions between biological entities at different complexity levels (see Figure 6 ). This visualization tool was developed ad-hoc for these projects [95] [96] [97] . 
Discussion
The analysis of the evolution of the disease networks carried out in the first part of the document shows how these models have become increasingly complex and allow to address arduous problems such as the improvement of our disease understanding or the repositioning of drugs with promising results. However, as a side effect of this growing complexity, new challenges have emerged that need to be addressed.
The growing availability of biological sources, key in the improvement of disease networks, is ballasted by their fragmentation, heterogeneity, availability and different conceptualization of their data [3] . Furthermore, these sources are intrinsically biased towards consolidated knowledge, which complicates the discovery of novel findings. The exploitation of textual sources such as clinical histories or scientific articles -more abundant and faster growing -allows researchers to compensate for these limitations. As an example of the abundance and potential of these alternative sources, in a recent study Westergaard extracted and analyzed 15 million English scientific full-text articles published during the period 1823-2016 [99] .
Despite this demonstrated potential, the exploitation of medical literature is not exempt from limitations. For instance, in the aforementioned study by Westergaard, the team could only access a subset of the Medline articles in full-text mode, while for the rest only the abstracts were available. In addition, depending on the source, they had to process documents with different structures and format. The use of open and structured sources such as Wikipedia has recently been proposed as an alternative [100] . Noise is also an important limiting factor when integrating new sources to enhance the predictive capacity of disease networks [101] . Adding new sources does not necessarily imply an improvement, since some databases are more informative than others. For example, Žitnik et al. evaluated the impact of removing sources in the performance of the proposed model to validate their informativeness. They observed that while the absence of some sources significantly affected the performance, in other case the impact was minimum [4] .
It is therefore necessary to counteract this effect by choosing algorithms which can weigh the relevance and confidence of various sources of information (either within a single dataset, or across datasets) and discard those irrelevant before constructing the model [49].
Validation is yet another challenge in the studies based on disease networks. In some cases, the absence of a gold standard leads to the use of previous studies for the validation of the new models [28, 82] , which might result in the propagation of errors from one study to another.
The use of curated sources and of sufficiently contrasted studies helps to partially alleviate this problem [49, 73] . Nevertheless, in the case of drug repositioning, the validation of a drug's ability to treat another disease ultimately requires in-vitro and in-vivo validations.
Related with the challenge of validation, the difficulty in accessing data from some studies prevents their reproducibility and verification by other teams, which makes them less reliable as references for future studies or as benchmarks. However, the effort of some researchers in making available the results of their work is worth to mention. Study cases such as Hetionet, Rephetio, SIGNOR and DisNOR [46, 47, 95, 96] , which offer advanced search and visualization tools, undoubtedly represent the path to follow.
The review of the process of creating a disease network from the point of view of a data science pipeline carried out in the second part of the document allows to compare how each study has faced these challenges. Supplementary Table 5 lists some of the most notable studies related to disease networks of the last decade, breaking down each of its phases. It also contains information on the type of problem addressed and the characteristics of the obtained network.
This table could be considered an extension/update of the one compiled by Sun K. et al. [41] .
Open questions and future lines of research
As a result of the systematized review of the literature on disease network reconstruction carried out in sections 2 and 3, and based on the previous discussion, we present in this section
some of the open questions in this area of research and propose future lines of work to address them.
Source integration
Given the upwards trend to integrate new sources for the construction of more complete Finally, as previously explained, the aggregation of sources to improve the completeness of disease networks has the introduction of noise as a collateral effect. How can this effect be avoided? In the study, some works addressing this problem have been presented, but given its importance, a more detailed research is required.
Methodology
Throughout our study, we reviewed the methods to build and analyze disease networks proposed by researchers over time. Supplementary Table 5 results; yet, this is still not available, as discussed below.
Validation
The difficulty in validating the results of studies based on disease networks has been highlighted in previous sections. 
Visualization
One of the main advantages of the use of biological networks in the improvement of our disease understanding is their intuitiveness. While the graphic visualization of the disease network is just another form of representation (not to be confused with the network itself), it facilitates its interpretation. However, as described in section 4. 
Conclusion
Research studies on based disease networks have significantly advanced over the last decade. From the initial simple undirected networks that associated diseases with symptoms or genes in a way, we have moved to complex networks that relate the disease to dozens of features from different sources in a semantic, directional and weighted way. The growing availability of biological and textual sources, the improvement in techniques and processing capacity and the use of new models have contributed fundamentally to this progress. As can be concluded from the analysis in the first part of the document, the contribution of disease networks to fields of disease understanding and drug repositioning is increasingly notable.
Nevertheless, an exhaustive analysis of the phases in the process of creating disease networks carried out in the second half of the document reveals important challenges. First, biological sources suffer from fragmentation, heterogeneity, lack of availability and different conceptualization, that can only be alleviated in part with the aggregation of textual sources.
Second, the combination of sources involves the introduction of noise that can affect the performance of the model, which makes it necessary to take preventive measures in this regard.
Finally, the scarcity of reference data and verifiable studies hinders the validation of the new models.
In addition to detecting these challenges, the analysis of disease networks from the point of view of their functional units allows for a more precise comparison of studies, highlighting their differences and common points. This study and the presented analyses, reflected in the summary tables, can serve to inspire future work. On one hand, a performance comparison of the prediction models accross the different studies might lead to deduce which functional units offer better results. On the other hand, the analysis of these units can facilitate the detection of unexploited sources or methods and explore them as alternatives. In a next phase, based on the obtained results, alternative combinations of these functional units could be proposed to build new pipelines and obtain more precise models based on disease networks. 
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